Site notifications

Sub menu

 
 

Authorised Prescriber established history of use lists

Check the list of medicines you can prescribe through the established history of use pathway as an Authorised Prescriber.

Last updated

We are updating our content for unapproved therapeutic goods. Please give your feedback.

If the medicine you want to access is on the lists, you can apply to become an Authorised Prescriber through the established history of use pathway. 

You must meet all the listed criteria to prescribe the product.

To apply, submit the form in the online system.

SAS and AP online system


Biologicals or medical devices aren't on the established history of use lists.

To access these products, use the standard pathway.

Read more about unapproved products for multiple patients (Authorised Prescriber).

Authorised Prescriber established history of use products

Active ingredientDosage formRoute of administrationIndicationCode
Allergens—multiple, various (including control solutions)DropsIntradermalConfirmation of suspected allergic reactionsAP2
Allergens – multiple, various (including control solutions)DropsSkin prickConfirmation of suspected allergic reactionsAP3
ArgipressinInjectionIntravenousTo increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholaminesAP147
ArgipressinInjectionIntravenousTreatment of uterine fibroidsAP157
AmilorideTabletOralTreatment of hypokalemiaAP158
Betaxolol 0.25% (preservative free)Eye drops OphthalmicTreatment of elevated intraocular pressure where other treatments are inappropriateAP5
Bismuth subcitrateTabletOralTreatment of resistant Helicobacter Pylori infectionAP6
BuspironeTabletOralTreatment of generalised anxiety disordersAP7
CalcitriolLiquidOralPrevention of hypophosphatemic rickets in childrenAP8
CalcitriolLiquidOralTreatment of hypoparathyroidism (with severe hypocalcaemia)AP9
CarbidopaTabletOralPremedication for F‑18 DOPA imagingAP10
Ciclosporin, 0.05%Eye drops, emulsionOphthalmicTreatment of suppressed tear production due to ocular inflammation associated with keratoconjunctivitis sicca (dry eye syndrome)AP26
CinnarizineTabletOralTreatment of vestibular disorders such as vertigo, tinnitus, nausea and vomiting (including Meniere’s disease) AP13
Clobetasol propionate 0.05%CreamTopicalTreatment, or prolongation of flare‑free intervals, of dermatitis/eczema where other treatments have failedAP14
Clobetasol propionate 0.05%LotionTopicalTreatment, or prolongation of flare‑free intervals, of dermatitis/eczema where other treatments have failedAP15
Clobetasol propionate 0.05%OintmentTopicalTreatment, or prolongation of flare‑free intervals, of dermatitis/eczema where other treatments have failedAP16
ClofazimineCapsuleOralTreatment of LeprosyAP17
ClofazimineCapsuleOralTreatment of granulomatous cheilitisAP18
ClofazimineCapsuleOralTreatment of Melkersson Rosenthal SyndromeAP19
ClofazimineCapsuleOralTreatment of confirmed mycobacterium avium paratuberculosis in immunocompromised patients recommended by an infectious disease specialistAP20
ClofazimineCapsuleOralTreatment of erythema nodosum leprosumAP21
ClofazimineCapsuleOralTreatment of drug resistant tuberculosisAP22
ClofazimineCapsuleOralTreatment of non-tuberculosis mycobacterial infectionsAP23
ClofazimineCapsuleOralTreatment of other infections as recommended by an infectious diseases specialistAP24
ColecalciferolCapsuleOralTreatment of severe vitamin D deficiency and prevention of osteoporosisAP11
ColecalciferolInjection IntramuscularTreatment of severe vitamin D deficiency and prevention of osteoporosisAP12
Cyclopentolate, 0.2%, and phenylephrine, 1%Eye dropsOphthalmicProduction of mydriasisAP25
DeflazacortTabletOralTreatment of Duchenne muscular dystrophyAP27
Dehydrated ethanol (alcohol) 96% ‑ 100%AmpouleTopicalTreatment of progressive keratoconus and intra‑operative use in superficial keratectomy (single use per procedure)AP28
Dexamethasone (preservative free)Eye dropsOphthalmicTreatment of inflammatory conditions of the eye that are non‑infected and steroid responsive in patients sensitive to preservative‑containing formulationsAP29
DiazoxideCapsuleOralTreatment of hypoglycaemiaAP30
DiazoxideCapsuleOralTreatment of hyperinsulinaemia AP31
DiazoxideCapsuleOralTreatment of Beckwith-Weiderman SyndromeAP32
DiazoxideCapsuleOralTreatment of insulinomaAP33
DiazoxideSuspensionOralTreatment of hypoglycaemiaAP34
DiazoxideSuspensionOralTreatment of hyperinsulinaemiaAP35
DiazoxideSuspensionOralTreatment of Beckwith-Weiderman SyndromeAP36
DiazoxideSuspensionOralTreatment of insulinomaAP37
DiazoxideTablet OralTreatment of hypoglycaemiaAP38
DiazoxideTablet OralTreatment of hyperinsulinaemiaAP39
DiazoxideTablet OralTreatment of Beckwith-Weiderman SyndromeAP40
DiazoxideTabletOralTreatment of insulinomaAP41
DiflunisalTabletOralTreatment of amyloidosisAP42
Dimethyl sulfoxide (DMSO)SolutionIntravesicalSymptomatic relief of interstitial cystitisAP43
DisulfiramTabletOralDeterrent to alcohol consumptionAP148
DoxycyclineInjectionIntralesionalSclerotherapy of lymphatic malformationsAP44
F‑18 DCFPyl (PSMA)InjectionIntravenousProstate cancer imaging studyAP45
F‑18 myocardial perfusion tracer (18F flurpiridaz)InjectionIntravenousMyocardial perfusion studyAP46
F‑18 NaF (sodium fluoride)InjectionIntravenousBone studyAP47
FamotidineInjectionIntravenousPrevention and management of hypersensitivity reactions to chemotherapyAP149
FlunarizineTabletOralTreatment of vestibular disordersAP48
FlunarizineTabletOralProphylactic treatment of migraineAP49
FlunarizineCapsuleOralTreatment of vestibular disordersAP50
FlunarizineCapsuleOralProphylactic treatment of migraineAP51
FurazolidoneTabletOralTreatment of resistant Helicobacter Pylori infectionAP52
Gallium‑68AerosolInhalationLung ventilation studyAP53
Ga‑68 - GalligasAerosolInhalationLung ventilation studyAP53
Gallium‑68InjectionIntravenousLung perfusion studyAP54
Ga‑68 ‑ MAAInjectionIntravenousLung perfusion studyAP54
Gallium‑68 prostate specific membrane antigen (PSMA)InjectionIntravenousProstate cancer imaging studyAP55
Gallium‑68 prostate specific membrane antigen (PSMA)InjectionIntravenousPET CT gallium-68 PSMA whole body uptake studyAP159
GanciclovirGelOphthalmicTreatment of cytomegalovirusAP160
Glycopyrronium bromideTabletOralTreatment of excessive salivation in patients with neurological conditionsAP56
Hyoscine hydrobromidePatchTransdermalTreatment of excessive salivationAP57
Hypertonic sodium chloride, 5 %Eye ointmentOphthalmicTemporary relief of corneal oedema (hypertonicity)AP58
Hypertonic sodium chloride, 5%Eye dropsOphthalmicTemporary relief of corneal oedema (hypertonicity)AP59
IloprostInjectionIntravenous infusionTreatment of patients with severe disabling Raynaud's phenomenon AP150
IloprostInjectionIntravenous infusionTreatment of peripheral ischaemiaAP151
Indigo carmineInjectionIntravenousIntraoperative detection of suspected urethral injuries during abdominal and pelvic surgical proceduresAP60
Indocyanine green dyeInjectionIntravenousIntra‑operative diagnostic useAP61
Interferon alpha‑2bEye dropsOphthalmicTreatment of ocular surface squamous neoplasiaAP152
KetotifenTabletOralTreatment of allergic conditionsAP62
LevofloxacinTabletOralTreatment of resistant Helicobacter Pylori infectionAP63
LevofloxacinTabletOralTreatment of drug resistant tuberculosisAP64
LevomepromazineTabletOralTreatment of nausea and vomitingAP65
LevomepromazineTabletOralTreatment of agitationAP66
LevomepromazineInjectionSubcutaneousTreatment of nausea and vomitingAP67
LevomepromazineInjectionSubcutaneousTreatment of agitationAP68
LifitegrastEye dropsOphthalmicTreatment of dry eye diseaseAP153
Lutetium‑177 (Lu 177) dotatateInjectionIntravenousTreatment of somatostatin receptor‑positive gastroenteropancreatic neuroendocrine tumors (GEP‑NETs)AP154
Lutetium‑177(Lu 177) Prostate Specific Membrane Antigen (PSMA)InjectionIntravenousTreatment of metastatic castration‑resistant prostate cancerAP155
MelatoninSyrupOralTreatment of sleep disordersAP70
MelatoninCapsuleOralTreatment of sleep disordersAP71
MelatoninImmediate release tabletOralTreatment of sleep disordersAP72
MelatoninLozengeOralTreatment of sleep disordersAP73
MetolazoneTabletOralTreatment of fluid overlaodAP161
MexiletineTabletOralTreatment of ventricular arrhythmiaAP74
MexiletineTabletOralTreatment of myotonic disordersAP75
MexiletineCapsuleOralTreatment of ventricular arrhythmiaAP76
MexiletineCapsuleOralTreatment of myotonic disordersAP77
Moxifloxacin 0.5%Eye dropsOphthalmicTreatment of refractory bacterial conjunctivitisAP78
NadololTabletOralTreatment of ventricular tachycardiaAP79
NadololTabletOralTreatment of long QT SyndromeAP80
Natamycin 5%Eye dropsOphthalmicTreatment of refractory fungal blepharitis, conjunctivitis or keratitisAP81
NeomycinTabletOralSepsis prevention for colorectal operationAP82
Nicotine in solution, salt or base formLiquid or solidInhalationSmoking cessation or management of nicotine dependence in patients aged 16 and overAP170
NifedipineImmediate release tabletOralTreatment of preterm labour AP156
NifedipineImmediate release tabletOralTreatment of pre‑eclampsiaAP141
NifedipineCapsuleOralTreatment of preterm labour AP142
NifedipineCapsuleOralTreatment of pre‑eclampsiaAP143
NitazoxanideTabletOralTreatment of giardiasisAP84
NitazoxanideTabletOralTreatment of cryptosporidiosisAP85
NitazoxanideTabletOralTreatment of blastocystisAP86
NitazoxanideSuspensionOralTreatment of giardiasisAP87
NitazoxanideSuspensionOralTreatment of cryptosporidiosisAP88
NitazoxanideSuspensionOralTreatment of blastocystisAP89
ParomomycinCapsuleOralAntiprotozoal treatment of Blastocystis hominisAP90
ParomomycinCapsuleOralAntiprotozoal treatment of Dientomoeba fragilisAP91
ParomomycinCapsuleOralAntiprotozoal treatment of Entamoeba histolyticaAP92
ParomomycinCapsuleOralAntiprotozoal treatment of any of parasite infectionAP93
PimozideTabletOralTreatment of schizophreniaAP94
PimozideTabletOralTreatment of chronic psychosisAP95
PimozideTabletOralTreatment of Tourette syndromeAP96
PristinamycinTabletOralTreatment of confirmed methicillin‑resistant Staphylococcus aureus or vancomycin‑resistant enterococci infection where there is history of failed therapy with the other available antibiotics, at sites in relation to bone/joint/prosthesisAP97
PristinamycinTabletOralTreatment of refractory or resistant mycoplasma genitalium infectionsAP98
PristinamycinTabletOralTreatment of other infections as prescribed by an infectious disease specialistAP99
ProgesteroneInjectionSubcutaneousTreatment of progesterone deficiencyAP144
Progesterone in oilInjectionIntramuscularTreatment of progesterone deficiencyAP145
PyrazinamideTabletOralTreatment of tuberculosisAP100
Riboflavin, 0.1% in 20% dextranEye dropsOphthalmicIntraoperative use in corneal collagen crosslinking (CXL) procedures for the treatment of progressive keratoconusAP101
Riboflavin, 0.1% in 1.1% hydroxylpropyl methylcellulose (HPMC)Eye dropsOphthalmicIntraoperative use in corneal collagen crosslinking (CXL) procedures for the treatment of progressive keratoconusAP102
Riboflavin, 0.1% in sodium chlorideEye dropsOphthalmicIntraoperative use in corneal collagen crosslinking (CXL) procedures for the treatment of progressive keratoconusAP103
Riboflavin, 0.22% in sodium chlorideEye dropsOphthalmicIntraoperative use in corneal collagen crosslinking (CXL) procedures for the treatment of progressive keratoconusAP104
Ripasudil 0.4%Eye dropsOphthalmicTreatment of refractory corneal oedemaAP105
Ripasudil 0.4%Eye dropsOphthalmicTreatment of refractory glaucomaAP106
Sodium benzoateTabletOralTreatment of urea cycle disordersAP107
Tacrolimus 0.03%OintmentTopicalTreatment, or prolongation of flare‑free intervals, of moderate to severe atopic dermatitis/eczema in childrenAP108
Tacrolimus 0.1%OintmentTopicalTreatment, or prolongation of flare‑free intervals, of moderate to severe atopic dermatitis/eczema in adultsAP109
Technetium‑99m (99m Tc) Prostate Specific Membrane Antigen (PSMA)InjectionIntravenousProstate cancer imaging studyAP146
TetracyclineCapsuleOralTreatment of resistant Helicobacter Pylori infectionAP110
TetracyclineTabletOralTreatment of resistant Helicobacter Pylori infectionAP111
Tick‑borne encephalitis vaccineInjectionIntramuscularPrevention of tick‑borne encephalitisAP112
TinidazoleTabletOralTreatment of trichomonas vaginalis infections of the genito‑urinary tract in female and male patientsAP113
TinidazoleTabletOralTreatment of giardiasisAP114
TinidazoleTabletOralTreatment of amoebic dysenteryAP115
TinidazoleTabletOralTreatment of amoebic liver abscessAP116
TinidazoleTabletOralTreatment of acute giardiasis in childrenAP117
TinidazoleTabletOralTreatment of acute amoebic dysentery in childrenAP118
TinidazoleTabletOralTreatment of amoebic liver disease in childrenAP119
TinidazoleTabletOralPrevention of infection of the surgical siteAP120
TizanidineCapsuleOralTreatment of spasticity where other treatments have failedAP121
TizanidineTabletOralTreatment of spasticity where other treatments have failedAP122
Triamcinolone acetonideSuspension for injectionOphthalmicTreatment of non‑infectious uveitisAP123
Triamcinolone acetonideSuspension for injectionOphthalmicVisualisation during vitrectomyAP124
Triamcinolone acetonideSuspension for injectionOphthalmicTreatment of diabetic macular oedemaAP125
Triamcinolone acetonideSuspension for injectionOphthalmicTreatment of cystoid macular oedema secondary to retinal vein occlusionAP126
Triamcinolone acetonideSuspension for injectionOphthalmicTreatment of uveitic macular oedemaAP127
Triamcinolone acetonideSuspension for injectionOphthalmicTreatment of post‑operative macular oedema (cataract surgery)AP128
VerteporfinPowder for injectionIntravenous infusionPhotosensitisation for photodynamic therapyAP129
Yttrium‑90 (Y‑90) CitrateInjectionIntraarticularRadiosynovectomy treatmentAP130

Medicinal cannabis products

Active ingredient category and circumstancesDosage formRoute of administrationIndicationCode

Category 1: CBD medicinal cannabis product (CBD ≥98%)

Circumstances:

  • a) cannabidiol comprises 98% or more of the total cannabinoid content of the medicine; and
  • b) any cannabinoids, other than cannabidiol, in the medicine are only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
liquidoralTreatment of refractory chronic pain in adult patientsAP131

Category 1: CBD medicinal cannabis product (CBD ≥98%)

Circumstances:

  • a) cannabidiol comprises 98% or more of the total cannabinoid content of the medicine; and
  • b) any cannabinoids, other than cannabidiol, in the medicine are only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
liquidoralTreatment of refractory anxiety in adult patientsAP132

Category 1: CBD medicinal cannabis product (CBD ≥98%)

Circumstances:

  • a) cannabidiol comprises 98% or more of the total cannabinoid content of the medicine; and
  • b) any cannabinoids, other than cannabidiol, in the medicine are only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients

 

liquidoral

Treatment of refractory sleep disorders in adult patients

 

AP162

Category 1: CBD medicinal cannabis product (CBD ≥98%)

Circumstances:

  • a) cannabidiol comprises 98% or more of the total cannabinoid content of the medicine; and
  • b) any cannabinoids, other than cannabidiol, in the medicine are only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients

 

liquidoral

Treatment of autism spectrum disorder in adult patients

 

AP163

Category 1: CBD medicinal cannabis product (CBD ≥98%)

Circumstances:

  • a) cannabidiol comprises 98% or more of the total cannabinoid content of the medicine; and
  • b) any cannabinoids, other than cannabidiol, in the medicine are only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients

 

liquidoral

Treatment and management of refractory cancer pain in adult patients

 

 

 

 

 

 

 

AP164

Category 1: CBD medicinal cannabis product (CBD ≥98%)

Circumstances:

  • a) cannabidiol comprises 98% or more of the total cannabinoid content of the medicine; and
  • b) any cannabinoids, other than cannabidiol, in the medicine are only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
capsuleoralTreatment of refractory chronic pain in adult patientsAP133

Category 1: CBD medicinal cannabis product (CBD ≥98%)

Circumstances:

  • a) cannabidiol comprises 98% or more of the total cannabinoid content of the medicine; and
  • b) any cannabinoids, other than cannabidiol, in the medicine are only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
capsuleoralTreatment of refractory anxiety in adult patientsAP134

Category 1: CBD medicinal cannabis product (CBD ≥98%)

Circumstances:

  • a) cannabidiol comprises 98% or more of the total cannabinoid content of the medicine; and
  • b) any cannabinoids, other than cannabidiol, in the medicine are only those naturally found in cannabis and comprise 2% or less of the total cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients

 

spray solutionoral

Treatment of refractory chronic pain in adult patients

 

 

 

 

 

 

 

AP165

Category 2: CBD dominant medicinal cannabis product (CBD ≥60% and <98%)

Circumstances:

  • a) cannabidiol derived from cannabis comprises 60% or more and less than 98% of the total cannabinoid content of the medicine; and
  • b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
liquidoralTreatment of refractory chronic pain in adult patientsAP135

Category 2: CBD dominant medicinal cannabis product (CBD ≥60% and <98%)

Circumstances:

  • a) cannabidiol derived from cannabis comprises 60% or more and less than 98% of the total cannabinoid content of the medicine; and
  • b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
liquidoralTreatment of refractory anxiety in adult patientsAP136

Category 2: CBD dominant medicinal cannabis product (CBD ≥60% and <98%)

Circumstances:

  • a) cannabidiol derived from cannabis comprises 60% or more and less than 98% of the total cannabinoid content of the medicine; and
  • b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients

 

liquidoralTreatment of refractory sleep disorders in adult patientsAP166

Category 2: CBD dominant medicinal cannabis product (CBD ≥60% and <98%)

Circumstances:

  • a) cannabidiol derived from cannabis comprises 60% or more and less than 98% of the total cannabinoid content of the medicine; and
  • b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients

 

liquidoralTreatment and management of refractory cancer pain in adult patientsAP167

Category 2: CBD dominant medicinal cannabis product (CBD ≥60% and <98%)

Circumstances:

  • a) cannabidiol derived from cannabis comprises 60% or more and less than 98% of the total cannabinoid content of the medicine; and
  • b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
capsuleoralTreatment of refractory chronic pain in adult patientsAP137

Category 2: CBD dominant medicinal cannabis product (CBD ≥60% and <98%)

Circumstances:

  • a) cannabidiol derived from cannabis comprises 60% or more and less than 98% of the total cannabinoid content of the medicine; and
  • b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
capsuleoralTreatment of refractory anxiety in adult patientsAP138

Category 3: Balanced medicinal cannabis product (CBD <60% and ≥40%)

Circumstances:

  • a) cannabidiol derived from cannabis comprises 40% or more and less than 60% of the total cannabinoid content of the medicine; and
  • b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
liquidoralTreatment of refractory chronic pain in adult patientsAP139

Category 3: Balanced medicinal cannabis product (CBD <60% and ≥40%)

Circumstances:

  • a) cannabidiol derived from cannabis comprises 40% or more and less than 60% of the total cannabinoid content of the medicine; and
  • b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients

 

liquidoralTreatment of refractory sleep disorders in adult patientsAP168

Category 3: Balanced medicinal cannabis product (CBD <60% and ≥40%)

Circumstances:

  • a) cannabidiol derived from cannabis comprises 40% or more and less than 60% of the total cannabinoid content of the medicine; and
  • b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients

 

liquidoralTreatment and management of refractory cancer pain in adult patientsAP169

Category 3: Balanced medicinal cannabis product (CBD <60% and ≥40%)

Circumstances:

  • a) cannabidiol derived from cannabis comprises 40% or more and less than 60% of the total cannabinoid content of the medicine; and
  • b) other cannabinoids (including tetrahydrocannabinol) derived from cannabis comprise the remaining cannabinoid content of the medicine; and
  • c) the medicine contains no other active ingredients
capsuleoralTreatment of refractory chronic pain in adult patientsAP140

Help us improve the Therapeutic Goods Administration site